TITLE

NEXMED LICENSES FEMPROX TO CJ CORP. FOR SOUTH KOREA

PUB. DATE
April 2004
SOURCE
Worldwide Biotech;Apr2004, Vol. 16 Issue 4, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that Femprox, a proprietary cream treatment for female sexual arousal disorder by NexMed, Inc., has been licensed by CJ Corp. for Korea. Terms of the agreement; Views of Hong-Chang Kim, president of Seoul, Korea-based CJ Pharmaceuticals, on their collaboration with NexMed; Background of NexMed.
ACCESSION #
12714950

 

Related Articles

  • Infectious Diseases News Round-Up.  // PharmaWatch: Monthly Review;Aug2009, Vol. 8 Issue 8, p21 

    The article offers world news briefs related to the pharmaceutical industry. Baxter International Inc. is developing an A/H1N1 vaccine using its Vero cell culture technology to respond the outbreak of H1N1 influenza. Novartis AG has received requests from over 30 governments for the delivery of...

  • Financings Roundup.  // BioWorld Today;5/15/2008, Vol. 19 Issue 95, p3 

    The article reports on a binding commitment entered by NexMed Inc. of East Windsor, New Jersey with one of its largest shareholders for a line of credit. The company intends to use the money to bridge the anticipated payments from partner Novartis AG, which licensed rights to NM100060 of NexMed....

  • Licensing agreements in the pharmaceutical industry. Simonet, Daniel // International Journal of Medical Marketing;Sep2002, Vol. 2 Issue 4, p329 

    This paper studies the licensing process, the mode of cooperation that is most Frequently encountered in the pharmaceutical sector. Within the framework of a licensing Agreement, the 'donor' transfers an innovation, a 'brand' and sometimes the raw material while the 'beneficiary' is committed to...

  • Drug licensing deals increase, as does failure rate.  // Medical Marketing & Media;Nov2001, Vol. 36 Issue 11, p8 

    Reports on the increase in drug licensing deals. Percentage of drug licensing deals; List of factors contribute to failures in drug licensing; Interest of pharmaceutical companies on drugs in phase II clinical trials.

  • 2014 Dealmakers Outlook: Start Early, Stay Late. Looney, William // Pharmaceutical Executive;Jul2014, Vol. 34 Issue 7, p16 

    Excerpts are presented that focuses on views of several notable people from pharmaceutical industry including Neel Patel, director, Campbell Alliance, Ravi Kiron, entrepreneur in Residence, SRI International and Mike Broxson, head global licensing, Takeda Pharmaceuticals on asset licensing.

  • County cannot license Canadian drugs. Holloway, Jacqueline // Las Vegas Business Press;5/24/2004, Vol. 21 Issue 20, p6 

    Provides insights on the regulation of storefront businesses wishing to facilitate the sale of Canadian pharmaceuticals to residents in Clark County in Nevada. Suggestion that the country should license the businesses before health, safety and legal questions are resolved; Emphasis that the...

  • Deals roundup.  // Medical Device Daily;7/9/2009, Vol. 13 Issue 130, p3 

    The article reports on the mutual decision of NexMed and Novartis to terminate their licensing agreement for NM100060, a topically-applied treatment for nail fungus. The licensing agreement was completed by the companies in September 2008. According to NexMed, the results of two Phase III...

  • NexMed Announces Patient Dosing in Phase 3 Program for Anti-Fungal Product.  // Equities;Apr2007, Vol. 55 Issue 2, p124 

    The article reports on the start of patient dosing in the Phase 3 clinical trials for NM100060 anti-fungal treatment of Novartis according to NexMed Inc. which signed a licensing agreement with the pharmaceutical firm. It states that two pivotal, randomized, double-blind and placebo-controlled...

  • NexMed's U.S. patent triggers a milestone payment from Novartis.  // Medical Device Daily;10/29/2008, Vol. 12 Issue 211, p8 

    The article reports that the U.S. Patent & Trademark Office has issued a notice of allowance for NexMed's U.S. patent application titled, "Antifungal Nail Coat and Method of Use." The patent covers NM100060, a topical application of terbinafine formulated with NexACT for the treatment of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics